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(EBRT) (50.4 Gy±10 Gy boost to primary tumor and/or to 
positive lymph nodes, ratio of 3D-CRT/IMRT: 105/28 pts) with 
concurrent cisplatin followed by 25-35 Gy of PDR IGABT in 30-
50 pulses. Combined intracavitary+interstitial (IC/S) 
technique was used in 6/133 cases. Dose–volume parameters 
of HR-CTV, IRCTV and D2cc OARs (organs at risk) were 
determined and converted into biologically equivalent doses 
in 2 Gy fractions (EQD2). Clinical outcome parameters (local 
control (LC), cancer specific survival (CCS) and overall 
survival (OS), progression free survival (PFS)) were analysed 
actuarially and Gr. 3-4 late morbidity crude rates were 
scored using CTCAEv3.0.  
Results: Mean follow-up was 36 months (range, 4–90). The 
mean D90 and D98 for HR-CTV was 82.7±12.3 Gy and 75±7.5 
Gy, while for IR-CTV was 68.7±4.2 Gy and 64.1±4.3 
respectively. The mean D2cc for OARs was the following: 
bladder: 78.2±10.3 Gy, rectum: 65.8±7.2 Gy, sigmoid: 
62.9±7.6 Gy and intestine: 63.3±9 Gy. Complete remission 
was achieved in 129/133 patients (97%). Three year LC, CSS 
and OS were: 90%, 79%, and 75%. The 3-year in-field regional- 
and distant control were 85% and 72%. Node negative 
patients had significantly higher 3-year PFS (92 vs. 60%, p= 
0.0005) and OS (86 vs. 60%, p= 0.002) compared to node 
positive ones. Late Gr. 3-4 morbidity was the following 
(events/pts): GI (fistula, obstruction, proctitis): 9 (6.7%)/6, 
GU (cystitis, haematuria, fistula): 7 (5.2%)/5, vaginal 
stenosis: 9 (6.8%)/9. 
Conclusions: The clinical outcome obtained in this large 
Belgian retrospective series along with the published 
literature support image-guided BT and radio-(chemo)therapy 
as optimal therapeutic approach for patients suffering LACC.  
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Purpose/Objective: To determine if the outcome on patients 
who present with low risk (PSA ≤ 10, Gleason Score (GS) ≤ 6 
and Clinical Stage (CS) ≤ T2a) or low intermediate risk (PSA 
between 10 - 20 and a GS ≤ 6 and CS ≤ T2c or GS =7 and PSA ≤ 
10 and CS ≤ T2c) prostate cancer and receive treatment with 
a single modality therapy of LDR intra-operatively planned 
prostate brachytherapy have similar outcomes. 
Materials and Methods: All patients were treated with the 
intra-operative planning system SPOT (R) with real time 
contouring, planning and an automated seed delivery system. 
Prescribed dose was 144Gy to the prostate and a margin (2-
5mm). Data was prospectively collected on all patients. 829 
patients with low-risk (517) and intermediate-risk (312) 
prostate cancer, defined by risk stratification as above, were 
implanted during this 10-year period between May 2003 and 
December 2013. All patients were followed at our institution 
by the treating physician with PSA measured at every 3 
months for first 2 years, then every 6 months for 3 years and 
yearly thereafter. 
Results: Median (range) follow-up for entire cohort was 4.4 
years (3 months – 10.6 years). Median age at diagnosis was 
63.1 years (95% CI 62.3 – 63.9). Mean PSA at diagnosis was 6.3 
(95% CI 6.2 – 6.5) and mean gland size was 36.7 cc (95% CI 
35.9 – 37.4). 93.3% of patients had CS ≤ T2a, 3.4% had CS ≥ 
T2b, and CS was unknown for 3.3% patients. 102 (12.3%) 
patients were given pre-operative hormone suppression, to 
downsize gland size. 11 (1.33%) patients had biochemical 
failure (BF), defined by nadir+2. Observed median time to BF 
was 4.4 years (1.0 – 8.9 years). 31 patients died within the 
follow-up period with 5 year overall survival was 98.4% (SE 
+/- 0.5%). Only 1/31 patient had BF and died of prostate 
cancer. 5 year biochemical progression free survival was 
98.6% (SE +/-0.5%). 10 patients with BF were from low-risk 
group, whereas only one patient from intermediate-risk 
group had BF. There was no statistical difference in failure 
between low-risk and intermediate-risk patients, log-rank 
P=0.395. Others factors including age at diagnosis (p=0.859), 
PSA (p=0.856), clinical stage (p=0.885), gland volume at the 
time of implant (0.219), hormones suppression prior to the 
implant (0.098) and dosimetric parameters [D90 (p=0.977), 
V150 (p=0.421) and V200 (p=0.211)] were not statistically 
significant in predicting BF. We attempted to fit these factors 
in a logistic regression model, however, none reached 
significance for association with BF. 
Conclusions: This is one of the largest series to report on 
outcomes of low dose rate brachytherapy performed using 
intra-operative planning. We report excellent clinical 
outcomes with a low rate of biochemical failure in both low 
and intermediate-risk patients  
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Purpose/Objective: Improved ultrasound image quality 
makes it possible to make a reliable reconstruction of the I-
125 seed implant and prostate contours at the end of the 
implantation procedure at the OR. The purpose of this study 
was to evaluate if the dose distribution based on these 
reconstructions is a reasonable estimate for the actual 
distributed dose. Combined CT and MR imaging made 1 
month after seed implantation was considered to be the 
golden standard for the determination of the actual 
distributed dose. 
Materials and Methods: Of 15 consecutive patients a trans-
rectal ultrasound scan was made at the end of the procedure 
at the OR (TRUS-d0). Type STM1251 I-125 seeds with a source 
strength of 0.57-0.60 µGy.h-1.m2 were used. Seeds and 
spacers of various lengths were assembled in strands (Prolink, 
Bard Brachytherapy). After 1 month a CT and a T2-weighted 
MRI scan were made of these patients (CT/MR-1m). The seed 
reconstruction was based on the CT images, the prostate 
contours on the MR images, and the dose distribution on the 
fusion of both scans. The prostate volume (Vp), V100, V200 and 
D90 were determined from both TRUS-d0 and CT/MR-1m. 
Motion of the seeds was evaluated by comparing the position 
of individual seeds with respect to the centre of mass of the 
delineated prostate (COMp). 
Results: The average ratio ±1SD of Vp, V100, V200 and D90 based 
on CT/MR-1m versus TRUS-d0 were 0.82±0.07, 0.97±0.05, 
1.51±0.28 and 0.97±0.14 respectively. Despite some large 
individual differences in V100 and D90 between both methods, 
the average values were not significantly different (p>0.05). 
Differences in Vp and V200 were, however, highly significant 
(p<0.001) between both methods. The ratio of the methods 
for the 'volume' of the implant (= average distance cubed of 
COMp to the seeds) was 0.85±0.09 (p<0.001). There was a 
significant caudal displacement of 2.9±2.7mm of the seeds in 
the CT/MR-1m compared to TRUS-d0 method (p=0.001). 
